

Laboratory Service Report

1-800-533-1710

Patient Name SAMPLEREPORT,GLIC	Patient ID SA00057322	Age 46	Gender F	Order # SA00057322
Ordering Phys CLIENT,CLIENT				DOB 06/10/1966
Client Order # SA00057322	Account Information			Report Notes
Collected 05/08/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 10/03/2013 15:47	Rochester, MN 55901			

Test	Flag Results	Unit	Reference Value	Perform Site*
CD8 Immune Competence, B RECEIVED: 05/09/2013 15:27 REF	OOPTED: 10/03/2012 13:36			
IFN-q	L 2.7	% CD8 T-Cells	10.3-56.0	MCR
CD107a/b	L 1.3	% CD8 T-Cells	8.5-49.1	MCR
Interpretation	1.5	. CDO I CEIIS	0.5 17.1	MCR

Decreased IFN-gamma production and CD107a/b expression after CD8 T cell stimulation. This result, on prima facie evidence, would suggest relatively significant immunosuppression, at least within the CD8 T cell compartment, likely related to post-transplant immunosuppression; though it is possible that there may be polyfunctional CD8 T cells present, producing other cytokines, such as TNF-alpha and/or IL-2 on activation instead of IFN-gamma. However, the decreased CD107 expression tends to support the former rather than the latter possibility. Correlate with other relevant immunological parameters and clinical status to assess the potential extent of immune compromise. Patient can be re-assessed for T cell function 1-2 weeks after reduction in Cellcept dose and also if steroids are decreased or weaned.

CD107a and CD107b are markers of cellular degranulation and surrogate markers for cytotoxic function.

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,GLIC	05/08/2013 00:00	Final
Page 1 of 1		** End of Report **